Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in New Hampshire: - New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
- Solinsky Center for Cancer Care — Manchester, New Hampshire
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in New Hampshire: - New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
- Solinsky Center for Cancer Care — Manchester, New Hampshire
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in New Hampshire: - New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
- The Dana-Farber Cancer Institute at Londonderry — Londonderry, New Hampshire
- Solinsky Center for Cancer Care — Manchester, New Hampshire
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in New Hampshire: - New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
- Solinsky Center for Cancer Care — Manchester, New Hampshire
Phase 3 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…
Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in New Hampshire: - Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in New Hampshire: - Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in New Hampshire: - Clinical Trial Site — Lebanon, New Hampshire
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in New Hampshire: - NH Oncology-Hematology, PA - Payson Center for Cancer Care — Concord, New Hampshire
- Dana-Farber Cancer Insitute at Londonderry Hospital — Londonderry, New Hampshire
- Solinsky Center for Cancer Care (NH Oncology-Hematology, PA) — Manchester, New Hampshire
- New England Cancer Specialists - Portsmouth — Portsmouth, New Hampshire
Phase 2 Recruiting Academic/Other
The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.
Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT05933395
Sites in New Hampshire: - Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
Phase 2 Recruiting Academic/Other
Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer
Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT05716516
Sites in New Hampshire: - Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
NA Recruiting Academic/Other
The goal of this clinical trial is to test the effect of an affect-based exercise prescription on moderate-vigorous physical activity participation among survivors of breast cancer who completed primary treatment within the last 5 years. T…
Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT06258993
Sites in New Hampshire: - Dartmouth-Hitchcock Clinic — Lebanon, New Hampshire
NA Recruiting Academic/Other
This trial is a study of 20 women with breast cancer to evaluate the addition of MR-guided (MRg) near-infrared spectroscopy (NIRS) with and without contrast, as part of a program to improve clinical management of women receiving breast mag…
Sponsor: Keith D. Paulsen
NCT ID: NCT06400563
Sites in New Hampshire: - Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire